# A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

> **NCT02161588** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 48 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Healthy

## Interventions

- **DRUG:** semaglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02161588
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161588, "A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02161588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*